{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:39:01Z","timestamp":1758044341782,"version":"3.44.0"},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"name":"The National Natural Science Foundation of China Science","award":["82173738"],"award-info":[{"award-number":["82173738"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Monoclonal antibody (mAb) drugs have become an important pillar of modern pharmaceutical fields. Owing to their high specificity and affinity, these drugs have shown broad application prospects in various fields, such as tumor therapy and autoimmune diseases. However, the pharmacokinetic profiles of mAbs are characterized by large individual differences that seriously affect drug efficacy and safety. Therefore, individualized drug delivery and therapeutic drug monitoring are key issues that must be addressed. Population pharmacokinetic (PPK) models contribute to therapeutic drug monitoring and provide a reference for individualized drug administration. Accordingly, the aim of this study was to review current PPK studies on mAb drugs and provide a reference for the clinical individualization of such drugs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>PubMed and China Knowledge Network were searched for relevant original research articles published between 2017 and 2024, and 30 articles were selected for a detailed review based on their titles and abstracts. These included 15 articles in the final analysis, whereas other relevant articles were selected from the reference list.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Among these 15 studies, 6 optimized the dosing regimen using the established PPK model, 6 studies only established the PPK model and require further pharmacodynamic studies to optimize the dosing regimen, and 2 studies are currently in the clinical trial phase of the drug.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This review of advances in PPK studies of mAb drugs reviews current PPK studies on mAb drugs to inform the clinical individualization of such drugs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001374","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T16:00:15Z","timestamp":1756310415000},"page":"565-575","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Population Pharmacokinetics of Monoclonal Antibody Drugs"],"prefix":"10.1097","volume":"47","author":[{"given":"Shouhua","family":"Mu","sequence":"first","affiliation":[{"name":"Pharmacy of the 940th Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, China; and"},{"name":"School of Pharmacy, Ningxia Medical University, Yinchuan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pharmacy of the 940th Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4635-576X","authenticated-orcid":false,"given":"Jingyan","family":"Jin","sequence":"additional","affiliation":[{"name":"Pharmacy of the 940th Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, China; and"},{"name":"School of Pharmacy, Ningxia Medical University, Yinchuan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinlian","family":"Tong","sequence":"additional","affiliation":[{"name":"Pharmacy of the 940th Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, China; and"},{"name":"School of Pharmacy, Ningxia Medical University, Yinchuan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JieLong","family":"Sun","sequence":"additional","affiliation":[{"name":"Pharmacy of the 940th Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, China; and"},{"name":"School of Pharmacy, Ningxia Medical University, Yinchuan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[{"name":"Pharmacy of the 940th Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Li","sequence":"additional","affiliation":[{"name":"Pharmacy of the 940th Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"R1-20250912","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/164_2019_323","article-title":"Monoclonal antibodies: past, present and future","volume":"260","author":"Posner","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"R2-20250912","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3390\/ph15050508","article-title":"Recent advances in translational pharmacokinetics and pharmacodynamics prediction of therapeutic antibodies using modeling and simulation","volume":"15","author":"Haraya","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"R3-20250912","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jcph.1633","article-title":"Parametric approaches in population pharmacokinetics","volume":"62","author":"Guidi","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"R4-20250912","doi-asserted-by":"crossref","first-page":"e00535","DOI":"10.1002\/prp2.535","article-title":"The pharmacology and therapeutic applications of monoclonal antibodies","volume":"7","author":"Castelli","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"R5-20250912","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s13318-019-00548-w","article-title":"Fluctuations in pharmacokinetics profiles of monoclonal antibodies","volume":"44","author":"Grabowski","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R7-20250912","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2005.12.041","article-title":"Target-mediated drug disposition and dynamics","volume":"72","author":"Mager","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"R8-20250912","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"R9-20250912","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12272-018-1087-2","article-title":"Targets of monoclonal antibodies for immunological diseases","volume":"42","author":"Yoo","year":"2019","journal-title":"Arch Pharm Res"},{"key":"R10-20250912","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1600-6143.2009.02987.x","article-title":"Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups","volume":"10","author":"Sis","year":"2010","journal-title":"Am J Transplant"},{"key":"R11-20250912","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/0966-3274(95)80027-1","article-title":"The OKT3 antibody response study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation","volume":"3","author":"Kimball","year":"1995","journal-title":"Transpl Immunol"},{"key":"R12-20250912","doi-asserted-by":"crossref","first-page":"6851","DOI":"10.1073\/pnas.81.21.6851","article-title":"Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains","volume":"81","author":"Morrison","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R13-20250912","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/00002371-199607000-00004","article-title":"Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma","volume":"19","author":"Albertini","year":"1996","journal-title":"J Immunother Emphasis Tumor Immunol"},{"key":"R14-20250912","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1389201003379059","article-title":"Rituximab: the first monoclonal antibody approved for the treatment of lymphoma","volume":"1","author":"Grillo-L\u00f3pez","year":"2000","journal-title":"Curr Pharm Biotechnol"},{"key":"R15-20250912","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1081\/CNV-100000074","article-title":"Herceptin: from the bench to the clinic","volume":"19","author":"Colomer","year":"2001","journal-title":"Cancer Invest"},{"key":"R17-20250912","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"R18-20250912","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2165\/00063030-199912020-00004","article-title":"Trastuzumab","volume":"12","author":"Perry","year":"1999","journal-title":"BioDrugs"},{"key":"R19-20250912","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.cji.0000192105.24583.83","article-title":"Fully human therapeutic monoclonal antibodies","volume":"29","author":"Weiner","year":"2006","journal-title":"J Immunother"},{"key":"R20-20250912","first-page":"2384","article-title":"Adalimumab","volume":"60","author":"Goto","year":"2002","journal-title":"Nihon Rinsho"},{"key":"R21-20250912","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/d41573-024-00064-w","article-title":"The antibody-drug conjugate landscape","volume":"23","author":"Flynn","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"R22-20250912","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1126\/science.1172253","article-title":"Immunology. Two-in-one designer antibodies","volume":"323","author":"Parren","year":"2009","journal-title":"Science"},{"key":"R23-20250912","first-page":"619","article-title":"Concentration-dependent nonlinear pharmacokinetics in critically ill patients: mechanisms and dosing implications","volume":"111","author":"Roberts","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"R24-20250912","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"R25-20250912","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.drudis.2018.05.030","article-title":"Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development","volume":"23","author":"Andersson","year":"2018","journal-title":"Drug Discov Today"},{"key":"R26-20250912","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/acs.bioconjchem.7b00062","article-title":"Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates","volume":"28","author":"Sun","year":"2017","journal-title":"Bioconjug Chem"},{"key":"R27-20250912","doi-asserted-by":"crossref","first-page":"148607","DOI":"10.1016\/j.gene.2024.148607","article-title":"Emerging trends and therapeutic applications of monoclonal antibodies","volume":"925","author":"Mekala","year":"2024","journal-title":"Gene"},{"key":"R28-20250912","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1111\/bcp.13991","article-title":"Nonlinear pharmacokinetics of rituximab in non-Hodgkin lymphomas: a pilot study","volume":"85","author":"Ternant","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"R29-20250912","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/bcp.13271","article-title":"Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome","volume":"83","author":"Rozman","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"R30-20250912","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1177\/0091270011430506","article-title":"Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia","volume":"52","author":"Li","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"R31-20250912","doi-asserted-by":"crossref","first-page":"1197651","DOI":"10.3389\/fphar.2024.1197651","article-title":"Dosing optimization of rituximab for primary membranous nephropathy by population pharmacokinetic and pharmacodynamic study","volume":"15","author":"Liang","year":"2024","journal-title":"Front Pharmacol"},{"key":"R32-20250912","doi-asserted-by":"crossref","first-page":"725665","DOI":"10.3389\/fphar.2021.725665","article-title":"Population pharmacokinetics of rituximab in pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"},{"key":"R33-20250912","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1111\/bcp.15339","article-title":"Population pharmacokinetics and exposure-response of anti-programmed cell death protein-1 monoclonal antibody dostarlimab in advanced solid tumours","volume":"88","author":"Melhem","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"R34-20250912","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1158\/1078-0432.CCR-22-3915","article-title":"Safety, efficacy, and biomarker analyses of dostarlimab in patients with endometrial cancer: interim results of the phase I GARNET study","volume":"29","author":"Oaknin","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R35-20250912","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1021\/acsptsci.3c00256","article-title":"Model-informed dose selection for a novel human immunoglobulin G4 derived monoclonal antibody targeting proprotein convertase kwashiorkor type 9: insights from population pharmacokinetics-pharmacodynamics and systems pharmacology","volume":"7","author":"Peng","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"key":"R36-20250912","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1158\/1078-0432.CCR-21-2662","article-title":"Model-based characterization of the bidirectional interaction between pharmacokinetics and tumor growth dynamics in patients with metastatic Merkel cell carcinoma treated with avelumab","volume":"28","author":"Grisic","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R37-20250912","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/FTD.0000000000000996","article-title":"Population pharmacokinetics of nivolumab in Japanese patients with nonsmall cell lung cancer","volume":"45","author":"Tohi","year":"2023","journal-title":"Ther Drug Monit"},{"key":"R38-20250912","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/jcph.1324","article-title":"Population pharmacokinetics and exposure\u2014safety analyses of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma","volume":"59","author":"Wang","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"R39-20250912","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/psp4.12143","article-title":"Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors","volume":"6","author":"Bajaj","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R40-20250912","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cpt.982","article-title":"Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status","volume":"103","author":"Baverel","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"R41-20250912","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40262-019-00804-x","article-title":"Population pharmacokinetics of an anti-PD-L1 antibody, durvalumab in patients with hematologic malignancies","volume":"59","author":"Ogasawara","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"R42-20250912","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed\/refractory classical Hodgkin lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J Clin Oncol"},{"key":"R43-20250912","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther"},{"key":"R44-20250912","first-page":"CD007356","article-title":"Rituximab for rheumatoid arthritis","volume":"1","author":"Lopez-Olivo","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R45-20250912","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1542\/pir.2020-001230","article-title":"Nephrotic syndrome","volume":"43","author":"Rodriguez-Ballestas","year":"2022","journal-title":"Pediatr Rev"},{"key":"R46-20250912","doi-asserted-by":"crossref","first-page":"871","DOI":"10.4314\/ahs.v20i2.41","article-title":"Efficacy and safety of rituximab for systemic lupus erythematosus treatment: a meta-analysis","volume":"20","author":"Wu","year":"2020","journal-title":"Afr Health Sci"},{"key":"R47-20250912","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2174\/1389200221666200719004035","article-title":"The influence of different disease states on rituximab pharmacokinetics","volume":"21","author":"Wang","year":"2020","journal-title":"Curr Drug Metab"},{"key":"R48-20250912","first-page":"5","article-title":"Epidemiology of non-Hodgkin's lymphoma","volume":"9","author":"Thandra","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"R49-20250912","doi-asserted-by":"crossref","first-page":"5636s","DOI":"10.1158\/1078-0432.CCR-07-1085","article-title":"Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma","volume":"13","author":"Martin","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R50-20250912","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1200\/JCO.22.01848","article-title":"Navigating the evolving treatment landscape of diffuse large B-cell lymphoma","volume":"41","author":"Nastoupil","year":"2023","journal-title":"J Clin Oncol"},{"key":"R51-20250912","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jpeds.2018.01.008","article-title":"Rituximab in the management of pediatric steroid-resistant nephrotic syndrome: a systematic review","volume":"197","author":"Jellouli","year":"2018","journal-title":"J Pediatr"},{"key":"R52-20250912","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.ekir.2020.12.035","article-title":"Rituximab in membranous nephropathy","volume":"6","author":"Gauckler","year":"2021","journal-title":"Kidney Int Rep"},{"key":"R53-20250912","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"R54-20250912","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.ki.5002395","article-title":"Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future","volume":"72","author":"Walsh","year":"2007","journal-title":"Kidney Int"},{"key":"R55-20250912","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"J Clin Oncol"},{"key":"R56-20250912","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1358\/dot.2021.57.3.3233363","article-title":"Dostarlimab for the treatment of endometrium cancer and other solid tumors","volume":"57","author":"Rubio-P\u00e9rez","year":"2021","journal-title":"Drugs Today (Barc)"},{"key":"R57-20250912","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3390\/medicina58111572","article-title":"Dostarlimab an inhibitor of PD-1\/PD-L1: a new paradigm for the treatment of cancer","volume":"58","author":"Alkholifi","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"R58-20250912","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00280-021-04358-3","article-title":"Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial","volume":"89","author":"Patnaik","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"R59-20250912","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2021.01.036","article-title":"Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019","volume":"161","author":"Gu","year":"2021","journal-title":"Gynecol Oncol"},{"key":"R60-20250912","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R61-20250912","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ygyno.2018.05.015","article-title":"Endometrial cancer: molecular markers and management of advanced stage disease","volume":"150","author":"Arend","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R62-20250912","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"R63-20250912","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"R64-20250912","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.2174\/1381612823666170130155036","article-title":"Anti-PCSK9 antibodies: a new era in the treatment of dyslipidemia","volume":"23","author":"Schmitz","year":"2017","journal-title":"Curr Pharm Des"},{"key":"R65-20250912","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/21645515.2018.1551671","article-title":"Product review: avelumab, an anti-PD-L1 antibody","volume":"15","author":"Collins","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"suppl 1","key":"R66-20250912","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41379-019-0394-6","article-title":"Danger is only skin deep: aggressive epidermal carcinomas. An overview of the diagnosis, demographics, molecular-genetics, staging, prognostic biomarkers, and therapeutic advances in Merkel cell carcinoma","volume":"33","author":"Tetzlaff","year":"2020","journal-title":"Mod Pathol"},{"key":"R67-20250912","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejca.2016.10.022","article-title":"Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs","volume":"71","author":"Schadendorf","year":"2017","journal-title":"Eur J Cancer"},{"key":"R68-20250912","doi-asserted-by":"crossref","first-page":"742","DOI":"10.6004\/jnccn.2018.0055","article-title":"Merkel cell carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Bichakjian","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"R69-20250912","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.annonc.2022.07.011","article-title":"First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin","volume":"33","author":"Iacovelli","year":"2022","journal-title":"Ann Oncol"},{"key":"R70-20250912","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1358\/dot.2014.50.7.2185913","article-title":"Current status of targeted therapy in non-small cell lung cancer","volume":"50","author":"Parums","year":"2014","journal-title":"Drugs Today (Barc)"},{"key":"R71-20250912","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cllc.2016.10.009","article-title":"Treatment design and rationale for a randomized trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small-cell lung cancer (RTOG 3505)","volume":"18","author":"Gerber","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"R72-20250912","doi-asserted-by":"crossref","first-page":"1753466618801167","DOI":"10.1177\/1753466618801167","article-title":"Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety","volume":"12","author":"Hida","year":"2018","journal-title":"Ther Adv Respir Dis"},{"key":"R73-20250912","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.1073\/pnas.94.17.9337","article-title":"Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells","volume":"94","author":"Braeuninger","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R74-20250912","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"R75-20250912","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ctrv.2018.08.001","article-title":"Patient-reported outcomes with nivolumab in advanced solid cancers","volume":"70","author":"Tykodi","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"R76-20250912","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s12094-020-02295-w","article-title":"SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)","volume":"22","author":"D\u00f3mine","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"R77-20250912","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1056\/NEJMc2313778","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer. Reply","volume":"390","author":"Heymach","year":"2024","journal-title":"N Engl J Med"},{"key":"R78-20250912","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1358\/dot.2017.53.12.2733054","article-title":"Durvalumab for the treatment of urothelial carcinoma","volume":"53","author":"Alsharedi","year":"2017","journal-title":"Drugs Today (Barc)"},{"key":"R79-20250912","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1158\/1078-0432.CCR-19-1680","article-title":"A single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma","volume":"25","author":"Song","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R80-20250912","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T12:02:01Z","timestamp":1757678521000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001374","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"type":"print","value":"0163-4356"},{"type":"electronic","value":"1536-3694"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"2024-12-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}